Persistence and Use of Ixekizumab in Patients with Psoriatic Arthritis in Real-World Practice in Spain. The PRO-STIP Study.

Rheumatol Ther · 2023 · PMC10468471 · PMID 37481752

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

In PRO-STIP, no differences in persistence were reported between the subgroups analyzed (gender, age, obesity); only a favorable trend for having a better persistence was observed in previous treatment with 0 and 1 previous b/tsDMARDs (vs. ≥ 2 b/tsDMARDs).

also in 377 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.